Lung cancer is the one of the most common types of cancer doctors diagnose each year in the U.S. The most common kind of lung cancer is non-small-cell lung cancer (NSCLC). It makes up around 84% ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
The Print on MSN1d
PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAYReport commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...
BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
About 10%-15% of all lung cancers today are SCLC. This type of lung cancer is less common than non-small-cell lung cancer (NSCLC), which accounts for nearly 87% of all lung cancer cases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback